RU2766094C2 - Антитела, нацеленные на антиген созревания в-клеток, и способы их применения - Google Patents

Антитела, нацеленные на антиген созревания в-клеток, и способы их применения Download PDF

Info

Publication number
RU2766094C2
RU2766094C2 RU2017123549A RU2017123549A RU2766094C2 RU 2766094 C2 RU2766094 C2 RU 2766094C2 RU 2017123549 A RU2017123549 A RU 2017123549A RU 2017123549 A RU2017123549 A RU 2017123549A RU 2766094 C2 RU2766094 C2 RU 2766094C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Application number
RU2017123549A
Other languages
English (en)
Russian (ru)
Other versions
RU2017123549A3 (enExample
RU2017123549A (ru
Inventor
Ренье Дж. БРЕНТДЖЕНС
Эрик Л. СМИТ
Чэн Лю
Original Assignee
Мемориал Слоан-Кеттеринг Кэнсер Сентер
Еурека Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоан-Кеттеринг Кэнсер Сентер, Еурека Терапьютикс, Инк. filed Critical Мемориал Слоан-Кеттеринг Кэнсер Сентер
Publication of RU2017123549A publication Critical patent/RU2017123549A/ru
Publication of RU2017123549A3 publication Critical patent/RU2017123549A3/ru
Application granted granted Critical
Publication of RU2766094C2 publication Critical patent/RU2766094C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2017123549A 2014-12-05 2015-12-04 Антитела, нацеленные на антиген созревания в-клеток, и способы их применения RU2766094C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088246P 2014-12-05 2014-12-05
US62/088,246 2014-12-05
PCT/US2015/064119 WO2016090327A2 (en) 2014-12-05 2015-12-04 Antibodies targeting b-cell maturation antigen and methods of use

Publications (3)

Publication Number Publication Date
RU2017123549A RU2017123549A (ru) 2019-01-14
RU2017123549A3 RU2017123549A3 (enExample) 2019-07-17
RU2766094C2 true RU2766094C2 (ru) 2022-02-07

Family

ID=56092678

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017123549A RU2766094C2 (ru) 2014-12-05 2015-12-04 Антитела, нацеленные на антиген созревания в-клеток, и способы их применения

Country Status (27)

Country Link
US (3) US10562972B2 (enExample)
EP (2) EP3872094A3 (enExample)
JP (3) JP6892822B2 (enExample)
KR (2) KR20240135036A (enExample)
CN (3) CN113429485A (enExample)
AU (2) AU2015357533B2 (enExample)
BR (1) BR112017011914A2 (enExample)
CA (1) CA2969877A1 (enExample)
CY (1) CY1124096T1 (enExample)
DK (1) DK3226897T3 (enExample)
ES (1) ES2861925T3 (enExample)
HR (1) HRP20210582T1 (enExample)
HU (1) HUE053995T2 (enExample)
IL (2) IL252624B (enExample)
LT (1) LT3226897T (enExample)
MX (1) MX2017007246A (enExample)
NZ (1) NZ732568A (enExample)
PH (1) PH12017501127A1 (enExample)
PL (1) PL3226897T3 (enExample)
PT (1) PT3226897T (enExample)
RS (1) RS61781B1 (enExample)
RU (1) RU2766094C2 (enExample)
SA (1) SA517381663B1 (enExample)
SG (2) SG10201901707QA (enExample)
SI (1) SI3226897T1 (enExample)
SM (1) SMT202100221T1 (enExample)
WO (1) WO2016090327A2 (enExample)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017007244A (es) 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Receptores de antigeno quimerico que se dirigen al antigeno de maduracion de celulas b y sus usos.
CN113429485A (zh) 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
SG10201913245UA (en) 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN109689686B (zh) 2016-10-07 2020-08-25 T细胞受体治疗公司 使用融合蛋白进行t细胞受体重编程的组合物和方法
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
CN108341872B (zh) 2017-01-23 2020-05-19 科济生物医药（上海）有限公司 靶向bcma的抗体及其应用
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US11965021B2 (en) 2017-04-26 2024-04-23 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP4327878A3 (en) 2017-05-01 2024-05-01 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
WO2019012015A1 (en) * 2017-07-12 2019-01-17 Iontas Limited POTASIC CHANNEL INHIBITORS
MX2020001491A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos y composiciones para preparar celulas geneticamente modificadas.
MX2020001490A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
BR112020005028A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento em combinação para câncer
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
EP3694878A1 (en) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
MX2020004243A (es) 2017-11-01 2020-09-25 Juno Therapeutics Inc Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
PE20200850A1 (es) 2017-11-01 2020-08-20 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
CN111787938A (zh) 2017-11-15 2020-10-16 诺华股份有限公司 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
KR102862251B1 (ko) 2017-12-08 2025-09-22 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법을 위한 표현형 마커 및 관련 방법
JP2021505168A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 操作されたｔ細胞の組成物を製造するための方法
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
AU2019214183B2 (en) * 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US11993658B2 (en) 2018-03-26 2024-05-28 Sutro Biopharma, Inc. Anti-BCMA antibodies and treatment methods
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
CN108642085A (zh) * 2018-06-11 2018-10-12 北京安斯晨睿生物科技有限公司 携带bcma突变抗原基因的重组腺相关病毒载体及其构建方法与应用
CA3100187A1 (en) * 2018-06-26 2020-01-02 Abl Bio, Inc. Anti-bcma antibody and use thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
SG11202100221VA (en) 2018-07-19 2021-02-25 Regeneron Pharma Chimeric antigen receptors with bcma specificity and uses thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
MX2021001519A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Metodos para valorar acidos nucleicos integrados.
ES3042082T3 (en) 2018-08-31 2025-11-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
JP2022509454A (ja) 2018-10-31 2022-01-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の処置法
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
US12263190B2 (en) 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
DK3886875T3 (da) 2018-11-30 2024-07-29 Juno Therapeutics Inc Behandlingsfremgangsmåder under anvendelse af adoptiv celleterapi
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
JP7631211B2 (ja) 2019-02-25 2025-02-18 ノバルティス アーゲー ウイルス送達のためのメソポーラスシリカ粒子組成物
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
AU2020322588A1 (en) * 2019-07-30 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
JP7515567B2 (ja) 2019-08-06 2024-07-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 生物医薬組成物及び関連する方法
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
EP4051402A1 (en) 2019-10-30 2022-09-07 Juno Therapeutics GmbH Cell selection and/or stimulation devices and methods of use
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
JP7714545B2 (ja) 2019-11-26 2025-07-29 ノバルティス アーゲー キメラ抗原受容体及びその使用
BR112022011964A2 (pt) * 2019-12-17 2022-09-06 Shenzhen Feipeng Biological Therapy Co Ltd Anticorpo de ligação a bcma e uso do mesmo
CN113061185B (zh) * 2020-01-02 2023-08-08 益科思特(北京)医药科技发展有限公司 一种bcma抗体的制备方法与应用
WO2021136323A1 (en) * 2020-01-03 2021-07-08 Salubris (Chengdu) Biotech Co., Ltd. Antibodies binding bcma and uses thereof
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
US20230055711A1 (en) * 2020-01-03 2023-02-23 Biosion Inc. Antibodies binding bcma and uses thereof
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
US20230087953A1 (en) 2020-02-12 2023-03-23 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
US20230165872A1 (en) 2020-04-28 2023-06-01 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
JP7791843B2 (ja) 2020-06-05 2025-12-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｂｃｍａ抗体－薬物コンジュゲート及び使用方法
EP4165169A1 (en) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitors and uses thereof
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
WO2022221737A1 (en) 2021-04-16 2022-10-20 Juno Therapeutics, Inc. T cell therapy in patients who have had prior stem cell transplant
US20240207310A1 (en) 2021-04-16 2024-06-27 Celgene Corporation Combination therapies with bcma-directed t cell therapy
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
AR125490A1 (es) 2021-04-30 2023-07-19 Celgene Corp Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi)
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
CN113527477B (zh) * 2021-07-23 2023-05-23 河南农业大学 猪源抗PDCoV-N蛋白的scFv及其表达载体、构建方法和应用
EP4380981A2 (en) 2021-08-03 2024-06-12 GlaxoSmithKline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
CA3229746A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN118159294A (zh) 2021-10-05 2024-06-07 葛兰素史密斯克莱知识产权发展有限公司 用于治疗癌症的联合疗法
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
JP2025516629A (ja) 2022-05-11 2025-05-30 セルジーン コーポレーション Ｔ細胞療法に関連する方法および使用、ならびにその生成
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
AU2023320568A1 (en) 2022-08-05 2025-02-06 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN120882418A (zh) * 2022-11-04 2025-10-31 MiNK治疗公司 B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
CN120303298A (zh) 2022-12-05 2025-07-11 葛兰素史密斯克莱知识产权发展有限公司 使用b细胞成熟抗原拮抗剂的治疗方法
AU2024214593A1 (en) 2023-02-03 2025-08-07 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
CN117069847B (zh) * 2023-10-08 2024-07-12 北京奇迈永华生物科技有限公司 靶向bcma抗体及其相关产品和医药用途
GB202317065D0 (en) 2023-11-07 2023-12-20 Coding Bio Ltd BCMA binding molecules
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104949A2 (en) * 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
US20110117093A1 (en) * 2000-06-16 2011-05-19 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to b lymphocyte stimulator protein
US20140161828A1 (en) * 2012-12-07 2014-06-12 Amgen Inc. Bcma antigen binding proteins

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
TR200201063T2 (tr) * 1999-08-17 2002-10-21 Biogen Inc. Bağışıklığı düzenleyici bir madde olan BAFF reseptörü (BCMA)
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP1468694A1 (en) 2001-12-27 2004-10-20 Sumitomo Pharmaceuticals Company, Limited Remedies for anorexia or lifestyle-related diseases and method of screening the same
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2007255388B2 (en) * 2006-06-06 2013-07-04 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
AU2008219972A1 (en) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
EP2132230B1 (en) 2007-03-22 2014-04-16 Genentech, Inc. Apoptotic anti-ige antibodies binding the membrane-bound ige
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
HUE044461T2 (hu) 2009-11-03 2019-10-28 Hope City Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz
SI2521568T1 (sl) * 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
JP2011178691A (ja) * 2010-02-26 2011-09-15 Takuya Ueda カテニン結合プローブとその用途
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
LT2961831T (lt) 2013-02-26 2020-11-10 Memorial Sloan Kettering Cancer Center Kompozicijos ir būdai, skirti imunoterapijai
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
JP2017515464A (ja) 2014-04-10 2017-06-15 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 細胞免疫療法のための方法および組成物
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
WO2016014789A2 (en) 2014-07-24 2016-01-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
MX2017007244A (es) 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Receptores de antigeno quimerico que se dirigen al antigeno de maduracion de celulas b y sus usos.
CN113429485A (zh) 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
WO2016094304A2 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
JP6957471B2 (ja) 2015-09-11 2021-11-02 バイオセプター・（ユーケー）・リミテッド キメラ抗原受容体およびその使用
WO2017087547A1 (en) 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
CA3061546C (en) 2017-04-28 2023-09-19 Julius-Maximilians-Universitat Wurzburg Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
EP4327878A3 (en) 2017-05-01 2024-05-01 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN107827989A (zh) 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
PE20200850A1 (es) 2017-11-01 2020-08-20 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117093A1 (en) * 2000-06-16 2011-05-19 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to b lymphocyte stimulator protein
WO2010104949A2 (en) * 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
US20140161828A1 (en) * 2012-12-07 2014-06-12 Amgen Inc. Bcma antigen binding proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RYAN M.C. et al. "Antibody targeting of B-cell maturation antigen on malignant plasma cells", Mol Cancer Ther 2007, Vol. 6(11), pp. 3009-3018. *
RYAN M.C. et al. "Antibody targeting of B-cell maturation antigen on malignant plasma cells", Mol Cancer Ther 2007, Vol. 6(11), pp. 3009-3018. НАСОНОВ Е.Л. "Белимумаб: прогресс в лечении системной красной волчанки", Науч-практич. ревматол., 2012, 54(5), с. 13-19. *
НАСОНОВ Е.Л. "Белимумаб: прогресс в лечении системной красной волчанки", Науч-практич. ревматол., 2012, 54(5), с. 13-19. *

Also Published As

Publication number Publication date
JP6892822B2 (ja) 2021-06-23
RU2017123549A3 (enExample) 2019-07-17
KR102701479B1 (ko) 2024-09-03
NZ732568A (en) 2023-03-31
IL252624B (en) 2021-09-30
WO2016090327A3 (en) 2016-07-21
US10947314B2 (en) 2021-03-16
KR20170108944A (ko) 2017-09-27
RS61781B1 (sr) 2021-06-30
PL3226897T3 (pl) 2021-08-30
HK1243956A1 (zh) 2018-07-27
SG10201901707QA (en) 2019-03-28
JP2018500014A (ja) 2018-01-11
US10562972B2 (en) 2020-02-18
AU2022200056A1 (en) 2022-02-03
CA2969877A1 (en) 2016-06-09
SA517381663B1 (ar) 2022-09-22
ES2861925T3 (es) 2021-10-06
CN107206076A (zh) 2017-09-26
EP3226897B1 (en) 2021-01-20
JP2021182933A (ja) 2021-12-02
HUE053995T2 (hu) 2021-08-30
EP3872094A2 (en) 2021-09-01
HRP20210582T1 (hr) 2021-09-03
SI3226897T1 (sl) 2021-08-31
LT3226897T (lt) 2021-05-25
EP3226897A4 (en) 2018-08-15
JP6959390B2 (ja) 2021-11-02
US20220315660A1 (en) 2022-10-06
US20200123266A1 (en) 2020-04-23
CN113429485A (zh) 2021-09-24
SMT202100221T1 (it) 2021-07-12
RU2017123549A (ru) 2019-01-14
DK3226897T3 (da) 2021-04-19
AU2015357533A1 (en) 2017-06-29
KR20240135036A (ko) 2024-09-10
PT3226897T (pt) 2021-04-13
PH12017501127A1 (en) 2018-03-05
EP3226897A2 (en) 2017-10-11
JP2020141680A (ja) 2020-09-10
IL252624A0 (en) 2017-07-31
CY1124096T1 (el) 2022-05-27
US11725059B2 (en) 2023-08-15
US20180118842A1 (en) 2018-05-03
WO2016090327A2 (en) 2016-06-09
MX2017007246A (es) 2018-01-25
CN107206076B (zh) 2021-07-09
SG11201704548PA (en) 2017-07-28
IL286124A (en) 2021-10-31
EP3872094A3 (en) 2021-12-08
BR112017011914A2 (pt) 2018-02-27
AU2015357533B2 (en) 2021-10-07
CN113388036A (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
RU2766094C2 (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
KR102602417B1 (ko) G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
HK40059306A (en) Antibodies targeting b-cell maturation antigen and methods of use
RU2774158C2 (ru) Антитела, направленные против fc-рецептор-подобного белка 5, и способы их применения
HK40058700A (en) Antibodies targeting b-cell maturation antigen and methods of use
HK1243956B (zh) 靶向b-细胞成熟抗原的抗体及其用途
HK40002168B (en) Antibodies targeting fc receptor-like 5 and methods of use
HK40002168A (en) Antibodies targeting fc receptor-like 5 and methods of use